

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mark Guthridge et al.

Application No.: 10/595,562

Confirmation No.: 2800

Filed: April 27, 2006

Art Unit: N/A

For: A BIDENTATE MOTIF AND METHODS OF
USE

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the date of entry of the national stage of an international application as set forth in 37 CFR 1.491 (37 CFR 1.97(b)(2)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: April 28, 2006

Respectfully submitted,

By  *Chandra Garry*
Chandra Garry

Registration No.: 57,895
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant

Substitute for form 1448A/B/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;">(Use as many sheets as necessary)</p>		Complete If Known Application Number 10/595,562-Conf. #2800 Filing Date April 27, 2006 First Named Inventor Mark Guthridge Art Unit N/A Examiner Name Not Yet Assigned Attorney Docket Number 03991/0204242-US0	
Sheet	1	of	2

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	AA*	US-5,112,951	05-12-1992	Hayashida et al.

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	BA	WO-98/21000	07-11-1998	Smithkline Beecham Corporation
	BB	WO-2005/040199 A1	05-06-2005	Medvet Science Pty Ltd

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	CA	Palacios, Carmen, et al., "The JNK phosphatase M3/6 is inhibited by protein-damaging stress", <i>Current Biology</i> , 2001, Vol. 11, pages 1439-1443.	
	CB	Stomaki, F.C. et al., "Identification of a 14-3-3 binding sequence in the common β chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 receptors that is serine-phosphorylated by GM-CSF", <i>Blood</i> , 1999, Vol. 94, No. 6, Pages 1993-1992.	
	CC	DATABASE NCBI (protein) Accession Number P46357, Leptin receptor.	
	CD	DATABASE NCBI (protein) Accession Number P40189, Interleukin-6 receptor.	
	CE	DATABASE NCBI (protein) Accession Number AAA16171, 16 May 1994 GM-CSF receptor beta chain.	
	CF	Lewis, R.E. et al., "Phorbol ester stimulates phosphorylation on serine 1327 of the human insulin receptor", <i>The Journal of Biological Chemistry</i> , 1994, Vol. 269, No. 42, pages 26259 - 26266.	
	CG	Merida, I. et al. "The serine-rich cytoplasmic domain of the interleukin-2 receptor β chain is essential for interleukin-2-dependent Tyrosine Protein Kinase and Phosphatidylinositol-3-Kinase Activation", <i>The Journal of Biological Chemistry</i> , 1993, Vol. 268, No. 42, pages 6765-6770.	
	CH	Paolini, R. et al. "Phosphorylation/dephosphorylation of high-affinity IgE receptors: A mechanism for coupling/uncoupling a large signaling complex", <i>Proceeding of the National Academy of Science USA</i> , 1992, Vol. 89, Pages 10733-10737.	
	CI	Imler, J.J. et al. "Identification of three adjacent amino acids of interleukin-2 receptor β chain which control its affinity and the specificity of the interaction with interleukin-2", <i>The EMBO Journal</i> , 1992, Vol. 11 No. 6, Pages 2047-2053.	
	CJ	Ferris, D K et al., "Interleukin 3 stimulation of tyrosine kinase activity in FDC-P1 cells", <i>Biochemical and Biophysical Research Communications</i> , 1988, vol. 154, No. 3, Pages 991-996.	
	CK	Gammeltoft, S et al., Review Article "Protein kinase activity of the insulin receptor", <i>The</i>	
Examiner Signature		Date Considered	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known	
		Application Number	10/595,562-Conf. #2800
		Filing Date	April 27, 2008
		First Named Inventor	Mark Guthridge
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Sheet	2	of	2
		Attorney Docket Number	03991/0204242-US0

	Biochemical Journal, 1986, Vol. 235, Pages 1-11.	
--	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--